Cosmo Bio Co

Cosmo Bio Co Gross Margin

The Gross Margin of Cosmo Bio Co (3386.T) as of Oct 27, 2026 is 34.39 %. In the previous year, Gross Margin was 33.17 % — a change of 3.67% (higher).

Gross Margin

34.39 %

YoY

3.67%

Last updated:

Gross Margin of Cosmo Bio Co is 2025 34.39 % . Gross Margin of Cosmo Bio Co was 2024 33.17 % . It decreases by 3.67% higher compared to the previous year.

For Cosmo Bio Co, the gross margin of 34.4% is down versus 39.6% a few years ago.

The Cosmo Bio Co Gross Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Gross Margin
Date
Gross Margin
Jan 1, 2018
36.62 JPY
Jan 1, 2019
37.94 JPY
Jan 1, 2020
38.95 JPY
Jan 1, 2021
39.64 JPY
Jan 1, 2022
36.02 JPY
Jan 1, 2023
34.80 JPY
Jan 1, 2024
33.17 JPY
Jan 1, 2025
34.39 JPY
The Cosmo Bio Co Gross Margin history
YEARGross MarginYoY
34.39 %+3.67%
33.17 %-4.68%
34.80 %-3.40%
36.02 %-9.13%
39.64 %+1.76%
38.95 %+2.65%
37.94 %+3.62%
36.62 %+2.22%
35.82 %-4.02%
37.32 %+15.32%
32.36 %-3.40%
33.50 %+7,787.62%
0.42 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cosmo Bio Co Stock analysis

What does Cosmo Bio Co do? Cosmo Bio Co., Ltd. generates revenue through the export, import, and sale of bio-research reagents, instruments, and software, as well as clinical diagnostics. The company imports research reagents primarily from the United States and Europe, which are utilized in life science research. In the equipment segment, Cosmo Bio handles specialized life science research equipment sourced from domestic and overseas suppliers, targeting domestic market sales. The equipment includes ultrasonic cell disruption devices, bioimaging systems, and research consumables. Clinical test drugs are sold mainly to hospitals and testing centers. The company's research reagents business focuses on importing products from the United States and Europe, which are prioritized for life science research applications. Equipment sales target domestic customers seeking specialized life science research tools, including ultrasonic cell disruption equipment and bioimaging-related devices. Clinical diagnostics products are distributed to hospitals and testing centers for medical testing purposes. Cosmo Bio's revenue streams are divided into three main segments: bio-research reagents, life science equipment, and clinical diagnostics. The reagents segment relies on imports from the United States and Europe, while the equipment segment features products like ultrasonic cell disruption equipment and bioimaging systems. Clinical diagnostics products are sold to hospitals and testing centers as test drugs for medical use. Cosmo Bio Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cosmo Bio Co stock

Gross Margin of Cosmo Bio Co is 34.39 % in 2025.

Gross Margin of Cosmo Bio Co changed from 33.17 % to 34.39 %, representing a 3.67% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Gross Margin Cosmo Bio Co since 2006 – with annual values, charts, and detailed analysis.

Gross Margin measures the percentage of revenue remaining after COGS. Higher gross margins indicate more efficient production and stronger pricing power.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Gross Margin's Cosmo Bio Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Gross Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Gross Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Cosmo Bio Co

All Key Metrics — Cosmo Bio Co